{
    "title": "114_hr931",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Helping Effective Antibiotics Last \nAct of 2015'' or the ``HEAL Act''.\n\nSEC. 2. APPROVAL OF CERTAIN DRUGS FOR USE IN A WELL-DEFINED POPULATION \n              OF PATIENTS.\n\n    (a) Approval of Certain Antibacterial.--Section 505 of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 355) is amended by adding at \nthe end the following:\n    ``(x) Approval of Certain Antibacterial Drugs for Use in a Well-\nDefined Population of Patients.--\n            ``(1) Unmet medical need defined.--In this subsection, the \n        term `unmet medical need' means that the antibacterial drug \n        involved--\n                    ``(A) has improved efficacy, as demonstrated in \n                adequate, well-controlled studies in humans, for \n                specific diseases or conditions, where current \n                therapies have been shown to be less effective;\n                    ``(B) has clinically meaningful decreased harms, \n                demonstrated in adequate, well-controlled studies in \n                humans, for diseases or conditions, where current \n                therapies have unacceptable adverse effects; or\n                    ``(C) has improved convenience, as demonstrated in \n                adequate, well-controlled studies in humans, where \n                improved convenience results in improved effectiveness \n                or decreased harms.\n            ``(2) Approval.--Upon receipt of an application under \n        subsection (b) for an antibacterial drug that is intended to \n        treat a serious or life-threatening disease or condition, \n        irrespective of whether the drug is intended to address an \n        unmet medical need, the Secretary--\n                    ``(A) may approve the drug under subsection (c) \n                only for treating a well-defined population of \n                patients, and based upon the results of clinical trials \n                inclusive of human subjects representative of such \n                well-defined population;\n                    ``(B) in determining whether to grant such \n                approval, shall rely on superior outcomes over \n                available therapies based on direct measures of patient \n                benefits, as demonstrated in adequate, well-controlled \n                studies in the well-defined patient population, such \n                as--\n                            ``(i) decreased mortality;\n                            ``(ii) irreversible morbidity; or\n                            ``(iii) validated surrogate endpoints that \n                        reflect mortality or irreversible morbidity; \n                        and\n                    ``(C) shall require the labeling of drugs approved \n                pursuant to this subsection to prominently include in \n                the prescribing information required by section 201.57 \n                of title 21, Code of Federal Regulations (or any \n                successor regulation)--\n                            ``(i) the population of patients with \n                        respect to which the added benefit over \n                        available therapies is expected as studied in \n                        adequate, well-controlled studies that form the \n                        basis for approval; and\n                            ``(ii) the method for identifying members \n                        of that population.\n            ``(3) Risk evaluation and mitigation strategy.--The \n        Secretary--\n                    ``(A) shall require a risk evaluation and \n                mitigation strategy (REMS) under section 505-1 for each \n                drug approved under this subsection; and\n                    ``(B) may include in any such strategy additional \n                elements to assure the safe use of the drug under \n                subsections (e) and (f) of section 505-1.\n            ``(4) Rule of construction.--Nothing in this subsection \n        shall be construed to alter the standards of evidence under \n        subsection (c) or (d) (including the substantial evidence \n        standard in subsection (d)). Subsections (c) and (d) and such \n        standards of evidence apply to the review and approval of drugs \n        under this subsection, including whether a drug is safe and \n        effective. Nothing in this subsection shall be construed to \n        limit the authority of the Secretary to approve products \n        pursuant to this Act and the Public Health Service Act as \n        authorized prior to the date of enactment of this subsection.\n            ``(5) Effective immediately.--The Secretary shall have the \n        authorities vested in the Secretary by this subsection \n        beginning on the date of enactment of this subsection, \n        irrespective of when and whether the Secretary promulgates \n        final regulations to carry out this subsection.''.\n    (b) Licensure of Certain Biological Products.--Section 351(j) of \nthe Public Health Service Act (42 U.S.C. 262(j)) is amended--\n            (1) by striking ``(j)'' and inserting ``(j)(1)'';\n            (2) by inserting ``505(x),'' after ``505(p),''; and\n            (3) by adding at the end the following:\n    ``(2) In applying section 505(x) of the Federal Food, Drug, and \nCosmetic Act to the licensure of biological products under this \nsection--\n            ``(A) references to an antibacterial drug with added \n        benefits over available therapies for a well-defined population \n        that is intended to treat a serious or life-threatening disease \n        or condition shall be construed to refer to biological products \n        with added benefits over available therapies for a well-defined \n        population intended to treat a bacterial infection associated \n        with a serious or life-threatening disease; and\n            ``(B) references to an application submitted under section \n        505(b) of such Act and to approval of a drug under section \n        505(c) of such Act shall be construed to refer to an \n        application submitted under subsection (a) of this section and \n        to licensure of a biological product under such subsection (a), \n        respectively.''.\n    (c) Monitoring.--Title III of the Public Health Service Act is \namended by inserting after section 317T (42 U.S.C. 247b-22) the \nfollowing:\n\n``SEC. 317U. MONITORING OF ANTIBACTERIAL DRUG USE, PATIENT OUTCOMES, \n              AND RESISTANCE.\n\n    ``(a) Monitoring.--The Secretary, acting through the Director of \nthe Centers for Disease Control and Prevention, shall use the National \nHealthcare Safety Network or another appropriate monitoring system to \nmonitor--\n            ``(1) changes in patient outcomes such as mortality and \n        irreversible morbidity causally related to antibacterial \n        resistance; and\n            ``(2) changes in bacterial resistance to drugs in relation \n        to patient outcomes.\n    ``(b) Public Availability of Data.--The Secretary, acting through \nthe Director of the Centers for Disease Control and Prevention, shall \nmake the data derived from monitoring under this section publicly \navailable for the purposes of--\n            ``(1) improving the monitoring of important trends in \n        patient outcomes in relation to antibacterial resistance; and\n            ``(2) ensuring appropriate stewardship of antibacterial \n        drugs, including those receiving approval or licensure for a \n        well-defined population pursuant to section 505(x) of the \n        Federal Food, Drug, and Cosmetic Act.''.\n\nSEC. 3. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROBIAL \n              ORGANISMS.\n\n    (a) In General.--Section 511 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 360a) is amended to read as follows:\n\n``SEC. 511. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROBIAL \n              ORGANISMS.\n\n    ``(a) In General.--The Secretary shall--\n            ``(1) identify upon approval or licensing of antibacterial \n        drugs (including biological products intended to treat a \n        bacterial infection and other types of antimicrobial drugs, as \n        deemed appropriate by the Secretary), including qualified \n        infectious disease products, susceptibility test interpretive \n        criteria for such drugs based upon patient outcomes of \n        mortality and morbidity from adequate and well-controlled \n        studies and such other confirmatory evidence as the Secretary \n        deems necessary; and\n            ``(2) update, consistent with subsection (b), such criteria \n        as needed based upon scientific evidence of changes in patient \n        outcomes.\n    ``(b) Responding to Changes in Patient Outcomes To Evaluate \nSusceptibility Test Interpretive Criteria.--\n            ``(1) In general.--As needed based on evidence related to \n        changes in patient outcomes, the Secretary shall--\n                    ``(A) evaluate any new scientific studies on \n                changes in patient outcomes in relation to \n                susceptibility test interpretive criteria; and\n                    ``(B) publish on the public Website of the Food and \n                Drug Administration a notice--\n                            ``(i) presenting suggested new or updated \n                        interpretive criteria; and\n                            ``(ii) if needed, hold a public advisory \n                        committee to discuss scientific evidence \n                        related to changes in interpretative criteria.\n            ``(2) Annual compilation of notices.--Each year, the \n        Secretary shall compile the notices published under paragraph \n        (1)(B) noting any changes from prior notices and publish such \n        compilation in the Federal Register.\n    ``(c) Definition.--In this section, the term `susceptibility test \ninterpretive criteria' means one or more specific values which \ncharacterize patient outcomes in relation to the degree to which \nbacteria or other microbes are more resistant to treatment as measured \nby patient outcomes.''.\n    (b) Conforming Amendment.--Section 1111 of the Food and Drug \nAdministration Amendments Act of 2007 (42 U.S.C. 247d-5a; relating to \nidentification of clinically susceptible concentrations of \nantimicrobials) is repealed.\n    (c) Report to Congress.--Not later than one year after the date of \nenactment of this Act, the Secretary of Health and Human Services shall \nsubmit to the Committee on Energy and Commerce of the House of \nRepresentatives and the Committee on Health, Education, Labor, and \nPensions of the Senate a report on the progress made in implementing \nsection 511 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n360a), as amended by this section.\n\nSEC. 4. REQUIRING DEMONSTRATION OF SUPERIOR OUTCOMES FOR QUALIFIED \n              INFECTIOUS DISEASE PRODUCTS TO RECEIVE AN EXTENDED \n              EXCLUSIVITY PERIOD.\n\n    Section 505E(g) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 355f(g)) is amended by striking ``means an antibacterial or \nantifungal drug for human use intended to treat'' and inserting ``means \nan antibacterial or antifungal drug for human use that is demonstrated \nto produce superior outcomes over available therapies, based on direct \nmeasures of patient benefits in clinical trials, and that is intended \nto treat''.\n\nSEC. 5. GUIDANCE ON TARGET PRODUCT PROFILES.\n\n    Not later than 18 months after the date of enactment of this Act, \nthe Commissioner of Food and Drugs, in consultation with the \nAdministrator of the Centers for Medicare & Medicaid Services, the \nDirector of the Indian Health Service, the Secretary of Defense, and \nthe Secretary of Veterans Affairs, shall issue guidance on the \ndevelopment of target product profiles for novel antibacterial drugs \nfocused on public health priorities."
}